Arsenic Trioxide

證據等級: L5

預測適應症: 10 個

Arsenic Trioxide: From Acute Promyelocytic Leukemia to Myelodysplastic Syndrome

One-Sentence Summary

Arsenic Trioxide (ATO) is an established anticancer agent best known for its transformative role in acute promyelocytic leukemia (APL), where the ATRA+ATO combination has become the global standard of first-line therapy. The TxGNN model predicts it may be effective for Myelodysplastic Syndrome (MDS) — placing MDS-related conditions at the top of its prediction ranking across multiple subtypes — with 24 clinical trials and 20 publications currently supporting this direction, including a 2023 systematic review and meta-analysis.

Quick Overview

Item	Content
Original Indication	Acute Promyelocytic Leukemia (APL) — established international standard with ATRA (no Taiwan FDA registration found in this dataset)
Predicted New Indication	Myelodysplastic Syndrome (MDS)
TxGNN Prediction Score	99.91%
Evidence Level	L2
Taiwan Market Status	Not marketed (0 registered licenses)
Number of NDAs	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Arsenic Trioxide acts through multiple converging mechanisms relevant to clonal hematologic disorders. In APL, ATO’s primary established mechanism is inducing selective degradation of the PML-RARα oncoprotein, triggering differentiation and apoptosis of leukemic blasts. Beyond this APL-specific effect, ATO exerts broader pro-apoptotic activity: it inhibits the NF-κB survival pathway in MDS CD34+ cells (PMID 16105982), downregulates anti-apoptotic BCL-2/BCL-XL while upregulating pro-apoptotic BAX (PMID 22964015), and generates reactive oxygen species (ROS) that disrupt mitochondrial integrity. These mechanisms are not restricted to APL and explain why ATO has been explored across a wider spectrum of hematologic malignancies.

The biological kinship between APL and MDS makes this prediction mechanistically coherent. Both arise from myeloid hematopoietic stem cell compartment dysfunction, characterized by aberrant clonal survival and impaired differentiation. In MDS specifically, ATO demonstrates a particularly attractive synergy with hypomethylating agents (HMAs): ATO promotes DNMT3A degradation and eliminates dysplastic clones, while Decitabine or Azacitidine concurrently re-activates silenced tumor suppressor genes — a mechanistically complementary combination that has shown enhanced cell killing in MDS cell lines (PMID 30898879). Additionally, ATO modulates the immunological imbalance in the bone marrow microenvironment by adjusting the Treg/Th17/Th1 ratio and suppressing inflammatory cytokines IFN-γ and IL-17 (PMID 38816179), addressing the immune dysregulation that drives ineffective hematopoiesis in MDS.

A 2023 systematic review and component network meta-analysis (PMID 37908176) — the highest currently available evidence tier — synthesized multiple Phase 2 trials and identified hematological response benefits and overall survival signals with ATO-containing regimens in MDS. Encouragingly, two oral ATO (Arsenol®) trials are actively recruiting as of 2025 (NCT06778187, NCT06670222), signaling sustained clinical investment and the potential for a more patient-friendly administration route. The primary remaining gap is the absence of a Phase 3 RCT dedicated to MDS; most MDS-specific Phase 2 trials were terminated early due to limited single-agent signals or resource constraints, reinforcing that combination strategies and careful patient selection are keys to further development.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00195104	Phase 1/2	Completed	87	ATO + low-dose cytarabine in high-risk MDS and poor-prognosis AML; largest directly relevant completed MDS trial; CR rate 17%, early mortality 8%; active and tolerable regimen
NCT02190695	Phase 2	Completed	92	Randomized comparison of Decitabine alone vs Decitabine+Carboplatin vs Decitabine+ATO in relapsed/refractory AML and MDS; provides comparative efficacy data for the ATO+HMA strategy
NCT00454480	Phase 2/3	Completed	2000	Treatment development programme for older patients with AML and high-risk MDS; largest safety dataset available, establishes real-world tolerability benchmarks for ATO in hematologic malignancies
NCT06778187	Phase 2	Recruiting	30	Oral ATO (Arsenol®) + ascorbic acid for TP53-mutated MDS, AML, and CMML; most recent trial (started Feb 2025), represents clinical translation of oral formulation in a genomically defined subgroup
NCT00671697	Phase 1	Completed	13	Decitabine + ATO + ascorbic acid triple combination in MDS and AML; completed, provides clinical validation of mechanistically synergistic triple regimen
NCT00251511	Phase 2	Terminated	60	ATO + Thalidomide across all IPSS risk groups in MDS; terminated but 60 patients enrolled providing meaningful safety and preliminary efficacy information
NCT00274781	Phase 2	Completed	30	ATO + Gemtuzumab Ozogamicin (Mylotarg) in advanced MDS; completed, explores antibody-drug conjugate combination in CD33+ dysplastic clones
NCT06670222	Phase 1	Recruiting	24	Oral ATO dose-escalation in low-risk MDS failing ESA and Luspatercept; started Jul 2025, establishes safe dose range for oral formulation in lower-risk patients
NCT00093366	Phase 1/2	Completed	32	ATO + Etanercept (TNF-α inhibitor) in advanced-stage MDS; completed, targets the inflammatory bone marrow microenvironment alongside cytotoxic ATO activity
NCT00621023	Phase 2	Completed	7	Decitabine + ATO + ascorbic acid pilot study in MDS; completed, confirms feasibility and provides initial safety signal for the triple combination

Literature Evidence

PMID	Year	Type	Journal	Key Findings
37908176	2023	Systematic Review & Meta-Analysis	Hematology	Network meta-analysis of ATO-containing regimens in MDS; demonstrates hematological response benefit and identifies optimal combinations, including ATO+HMA; highest current evidence tier
40167011	2025	Retrospective Study	Hematology	Decitabine + ATO in elderly high-risk MDS patients; confirms clinical activity and manageable toxicity in a fragile, treatment-limited population
38816179	2024	Comparative Study	Immunopharmacology & Immunotoxicology	Compares immunological changes between oral realgar (arsenic disulfide) and IV ATO in MDS mouse model; characterizes immune pathway modulation and supports route-of-delivery research
20956016	2011	Phase I/II Clinical Study	Leukemia Research	ATO + low-dose cytarabine in 49 patients with intermediate-2/high-risk MDS; CR in 17%, active regimen with manageable toxicity profile
18282365	2007	Clinical Data Review	Clinical Lymphoma & Myeloma	Multi-trial synthesis of ATO data in leukemias and MDS; documents response patterns and contextualizes MDS findings within the broader ATO clinical experience
22964015	2012	Translational Clinical Study	J Hematol Oncol	Ex vivo analysis of 93 apoptosis-related genes in MDS patients before and after ATO treatment; identifies BCL-2 family downregulation as a key in vivo mechanism of action
16105982	2005	In Vitro/Mechanistic	Blood	ATO inhibits NF-κB via FLIP downregulation in MDS CD34+ cells, selectively inducing apoptosis in high-grade MDS (RAEB) while sparing normal marrow; defines subtype-specific activity
30898879	2019	In Vitro Mechanistic Study	J Investigative Medicine	ATO + Decitabine synergistically kill MDS cells (MUTZ-1, SKM-1) via ER stress-triggered apoptosis; provides mechanistic rationale for the HMA combination strategy
17920679	2008	Clinical Study	Leukemia Research	ATO + all-trans retinoic acid + thalidomide in higher-risk MDS; evaluates a multi-agent differentiation-plus-immunomodulation approach in a clinical cohort
31775455	2019	Retrospective Clinical Study	Zhonghua Nei Ke Za Zhi	Low-dose subcutaneous Decitabine + ATO in 11 intermediate/high-risk MDS patients; CR in 3 (27%), hematological improvement in 6 (55%); supports low-dose combination feasibility

US Market Information

No registered drug licenses for Arsenic Trioxide were found in the Taiwan FDA (TFDA) database queried for this report.

Note: Arsenic Trioxide (brand name Trisenox®, Teva) is FDA-approved in the United States for APL since September 2000. The absence of Taiwan registrations in this dataset may reflect a lack of formal TFDA registration rather than a global non-approval status. Clinicians in Taiwan may access the drug through named-patient or compassionate use pathways.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (arsenic-based agent) — acts via ROS generation, mitochondrial pathway apoptosis, NF-κB inhibition, and targeted oncoprotein degradation (PML-RARα in APL)
Myelosuppression Risk	Moderate — leukocytosis and APL differentiation syndrome in APL setting; neutropenia, thrombocytopenia, and anemia reported in MDS/hematologic malignancy trials
Emetogenicity Classification	Low to moderate
Monitoring Items	QTc interval by ECG before and during each cycle (critical — QT prolongation risk), CBC with differential, serum electrolytes (potassium ≥4 mEq/L, magnesium ≥1.8 mg/dL mandatory), liver function tests (AST/ALT/bilirubin), serum creatinine
Handling Protection	Must follow cytotoxic drug handling regulations (NIOSH guidelines); appropriate PPE required during preparation and administration

Safety Considerations

Please refer to the package insert for safety information.

Critical known risks: Arsenic Trioxide carries FDA black-box warnings for QT interval prolongation (risk of fatal arrhythmias, particularly torsades de pointes) and APL differentiation syndrome (potentially fatal pulmonary/vascular complication). Electrolyte correction and baseline ECG assessment are mandatory before initiating therapy. Co-administration with other QT-prolonging agents must be avoided or carefully managed.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A 2023 systematic review and meta-analysis (PMID 37908176), multiple completed Phase 2 trials including randomized and multi-center designs (NCT02190695, N=92; NCT00195104, N=87), and two actively recruiting oral ATO trials in MDS (NCT06778187, NCT06670222 — both started in 2025) together constitute L2-level evidence supporting ATO’s clinical activity in MDS. The mechanistic synergy with hypomethylating agents is documented at both the preclinical and clinical levels, and the emergence of oral ATO (Arsenol®) addresses historical barriers related to IV administration burden.

To proceed, the following is needed:

A dedicated Phase 3 RCT comparing ATO+HMA (e.g., Decitabine or Azacitidine) versus HMA alone in MDS — this is the critical missing piece for regulatory-grade evidence
Results from the two active oral ATO trials (NCT06778187, NCT06670222) before committing to an IV-only development strategy
Patient selection biomarkers to identify MDS subtypes most likely to respond (e.g., TP53-mutated disease, high-risk IPSS-R category, HMA-refractory patients)
Formal QT monitoring protocol and mandatory electrolyte management plan embedded in any MDS trial design
Mechanism of action (MOA) documentation from DrugBank or literature review to complete the pharmacological profile for regulatory submissions
TFDA registration pathway assessment, given zero existing Taiwan licenses
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.